NCT05471505View on ClinicalTrials.gov

Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding

CompletedOBSERVATIONAL
Enrollment

120,722

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions
Non-valvular Atrial Fibrillation
Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05471505 - Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding | Biotech Hunter | Biotech Hunter